31st Mar 2015 13:17
LONDON (Alliance News) - UK-based drugmaker AstraZeneca PLC Tuesday said MOVANTIK (naloxegol) has been launched in the US.
On September 16, 2014, the US Food and Drug Administration approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist or PAMORA medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
The FDA approval of MOVANTIK was based on data from the KODIAC clinical program. In the KODIAC-04 and KODIAC-05 trials, response rates at 12 weeks were significantly higher with MOVANTIK 25 mg compared with placebo.
The most common adverse reactions with MOVANTIK were abdominal pain, diarrhea, nausea, flatulence, vomiting, headache, and hyperhidrosis.
Copyright RTT News/dpa-AFX
Related Shares:
Astrazeneca